Literature DB >> 10980538

A cluster of lysinuric protein intolerance (LPI) patients in a northern part of Iwate, Japan due to a founder effect. The Mass Screening Group.

A Koizumi1, Y Shoji, J Nozaki, A Noguchi, X E, M Dakeishi, T Ohura, K Tsuyoshi, W Yasuhiko, M Manabe, Y Takasago, G Takada.   

Abstract

Lysinuric protein intolerance is an autosomal recessive disease characterized by defective transport of the dibasic aminoacids. Mutational analysis of LPI patients in the northern part of Japan revealed that six were homozygous for the R410X mutation and two others were compound heterozygotes of R410X and other unknown mutations. In the population epidemiology study in a local cluster in the northern part of Iwate, ten heterozygotes were found in 1190 newborn babies leading to an estimated LPI incidence of 1/57,000. Polymorphism analysis revealed two major alleles, A and B, in intron 8. While the population frequency of allele A was 0.9 and that of allele B was 0.1 in the northern part of Japan the R410X mutations were exclusively on allele B in 31 chromosomes suggesting a founder effect. Genetic analysis in patients revealed strong linkage disequilibrium with D14S283 and TCRA indicating that the R410X mutation occurred before at least 130 generations ago (about 2600 years). The R410X mutation was shown to be useful as a molecular marker for screening LPI patients in the northern part of Japan. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980538     DOI: 10.1002/1098-1004(200009)16:3<270::AID-HUMU14>3.0.CO;2-J

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  9 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  Impaired portal circulation resulting from L-arginine deficiency in patients with lysinuric protein intolerance.

Authors:  T Takeda; H Watanabe; T Saito; K Saito; H Takeda; H Togashi; J Fujii; Y Takasago; S Kawata
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  Lung involvement in children with lysinuric protein intolerance.

Authors:  Sarah Valimahamed-Mitha; Laureline Berteloot; Héloise Ducoin; Chris Ottolenghi; Pascale de Lonlay; Jacques de Blic
Journal:  J Inherit Metab Dis       Date:  2014-10-22       Impact factor: 4.982

4.  Urine Beta2-Microglobulin Is an Early Marker of Renal Involvement in LPI.

Authors:  Mari Kärki; Kirsti Näntö-Salonen; Harri Niinikoski; Laura M Tanner
Journal:  JIMD Rep       Date:  2015-06-30

Review 5.  Overview of symptoms and treatment for lysinuric protein intolerance.

Authors:  Atsuko Noguchi; Tsutomu Takahashi
Journal:  J Hum Genet       Date:  2019-06-18       Impact factor: 3.172

6.  The first Korean case of lysinuric protein intolerance: presented with short stature and increased somnolence.

Authors:  Jung Min Ko; Choong Ho Shin; Sei Won Yang; Moon Woo Seong; Sung Sup Park; Junghan Song
Journal:  J Korean Med Sci       Date:  2012-07-25       Impact factor: 2.153

7.  SP-D counteracts GM-CSF-mediated increase of granuloma formation by alveolar macrophages in lysinuric protein intolerance.

Authors:  David N Douda; Nicole Farmakovski; Sharon Dell; Hartmut Grasemann; Nades Palaniyar
Journal:  Orphanet J Rare Dis       Date:  2009-12-23       Impact factor: 4.123

8.  Immune Dysregulation Mimicking Systemic Lupus Erythematosus in a Patient With Lysinuric Protein Intolerance: Case Report and Review of the Literature.

Authors:  Josefina Longeri Contreras; Mabel A Ladino; Katherine Aránguiz; Gonzalo P Mendez; Zeynep Coban-Akdemir; Bo Yuan; Richard A Gibbs; Lindsay C Burrage; James R Lupski; Ivan K Chinn; Tiphanie P Vogel; Jordan S Orange; M Cecilia Poli
Journal:  Front Pediatr       Date:  2021-05-20       Impact factor: 3.418

9.  Inducible Slc7a7 Knockout Mouse Model Recapitulates Lysinuric Protein Intolerance Disease.

Authors:  Susanna Bodoy; Fernando Sotillo; Meritxell Espino-Guarch; Maria Pia Sperandeo; Aida Ormazabal; Antonio Zorzano; Gianfranco Sebastio; Rafael Artuch; Manuel Palacín
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.